Lipopeptide Immunisation With GTU-multiHIV Trial

Inclusion criteria: * Documented HIV-1 infection (ELISA and Western blot) * Age ≥ 18 years and \< 60 years * No history of CDC category C clinical events (1993), including cutaneous Kaposi's sarcoma * CD4 Nadir ≥ 300/mm3 Under antiretroviral treatment * CD4 ≥ 600/mm3 on all measurements within the previous 6 months\* prior to W-3 screening visit (one single CD4 value between 550-600 cells/ mm3 is permitted) * CD4 value ≥ 600/ mm3 at W-3 screening visit * Plasma HIV1-RNA \< 50 copies/mL on all measurements within the previous 6 months\* (An occasional measurement of HIV-1 RNA (so-called " blip " between 50 and 200 copies/mL is permitted) * HIV1-RNA \< 50 copies/mL at W-3 screening visit \* In the absence of measurement in the last 6 months, a measurement performed in the last 12 months is accepted * Treatment with a combination of antiviral drugs (cART) for at least 18 months regardless of the combination, under condition that : * in the W24 visit the non-nucleoside inhibitors are replaced by a protease inhibitor potentiated by ritonavir * no failure or resistance to the protease inhibitor was previously reported * With adequate method of contraception and negative pregnancy test (βHCG plasma) for women of childbearing potential * Laboratory parameters at W-3: * polynuclear neutrophils ≥ 1,000/mm3 * haemoglobin ≥ 10 g/dl * platelets ≥ 100,000/mm3 * creatinine ≤ 1.5 x N * AST, ALT, bilirubin ≤ 2.5 x N * proteinuria ≤ 1 g/L (++) * anti-nuclear antibodies ≤ 1/320 * anticardiolipin antibodies ≤ 30 U * no lupus anticoagulant * Participant agreeing to be treated and followed for at least 74 weeks according to the protocol * Participant agreeing to interrupt his/her cART treatment and, if applicable, to replace the non-nucleoside inhibitors by a protease inhibitor potentiated by ritonavir at W24 * Participant agreeing to the use of condom, in particular during ART interruption period (between the visit S36 and the visite S48) * Participant covered by HealthInsurance (article L1121-11 of Code de la Santé Publique) * Written informed consent (at the latest the day of pre-inclusion and before all exams to be done in the context of the trial) (article L1122-1-1 of Code de la Santé Publique). Exclusion criteria * Pregnancy or lactation, * HIV-2 infection (isolated or associated with HIV-1), * History of (experimental) vaccinations against HIV, * Treatment with chemotherapy or interferon alpha (IFN-α-2b), sargramostim (GM-CSF), IL-2 or IL-7 ongoing or in the previous12 weeks before inclusion (W0), * Treatment with corticoids or immunosuppressive agents ongoing or in the previous12 weeks before inclusion in the trial (W0), * Administration of a live vaccine within 60 days prior to inclusion in the trial (W0) or any other inactivated vaccine within 14 days before W0 visit * Planned administration, during the follow-up of participants, of a vaccine other than those recommended in France as part of the usual care of patients * History of cancer (except basal cellular skin carcinoma), * History of cardiovascular disease (angina, myocardial infarction, transient ischemic attack, stroke), * History of renal failure related to HIV, * History of thrombocytopenia related to HIV (\<50,000/mm3), * Ongoing cardiac, pulmonary, thyroid, renal or neurological (peripheral or central) diseases, * Progressive infection, * Co-infection with hepatitis B (HBsAg + or isolated anti-HBc antibodies +) or hepatitis C (anti-HCV antibody and PCR +), * Known allergy to aminoglycosides, * Person placed under juridical protection (article L1122-2 of Code de la Santé Publique) * Person participating in another biomedical research with an exclusion period always ongoing at screening.